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Abstract: 
Background: Problems may arise with insulin treatment, due to patients’ perspective towards it leading to refusal. 
Objectives: To evaluate diabetic patients’ refusal towards insulin therapy, and to assess patients' perception and perceived bar-
riers towards insulin. 
Methods: A cross-sectionalstudy, where type 2 diabetics participated in the study during a period, February through March 
2017. They were interviewed in person by a questionnaire including three sections; socio-demography, medical history and a 
health belief  model, comprising barriers to use insulin. Five points Likert scale was used to measure patients’ perception and 
barriers towards insulin therapy. 
Results: One fourth (24.4%) of  the diabetic patients refused insulin. Among the controlled group, 34.4% refused insulin, while 
21% refused insulin among the uncontrolled group. The study showed different barriers towards insulin therapy, including fear 
of  injection, pain, insulin injection needs help from others, fear of  hypoglycaemia and embarrassment. 
Conclusion: Diabetics showed a negative attitude towards insulin therapy due to social and psychological factors. The results 
necessitate the development of  a strategy to address problems related with a reluctance to initiate insulin and put a strategy to 
implement education and better interaction with diabetic team to the stigma from phobia from insulin use.
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Introduction 
All over the world, an estimated 382 million people are 
living with diabetes, and this number is expected to rise 
to 592 million by 20351. The World Health Organization 
(WHO) has reported that Saudi Arabia ranks the second 
highest in the Middle East and is the seventh in the world 
for the rate of  increasing number of  diabetes cases. It 
is estimated that around 7 million of  the Saudi popula-
tion are diabetics and around 3 million have pre-diabetes. 
Diabetes has approximately registered a ten-fold increase 
over the past three decades in Saudi Arabia2.
For the management of  diabetes, there are various oral 
hypoglycemic drugs (OHDs) that are available worldwide. 
Recommendations for their use either as monotherapy or 
in combination with or without insulin are described in 
many of  diabetes management guidelines including the 
American Diabetes Association (ADA) guidelines3. 
Insulin is eventually required for control of  diabetes when 
secondary failure of  β-cells of  pancreas occurs down the 
course of  the disease. One of  the main problems associ-
ated with insulin therapy is the delay in initiation of  treat-
ment up to complete refusal by the patient due to differ-
ent perspectives and health beliefs. This results in many 
complications which inflicts a huge burden on the health 
care budget as well as economy of  the country4. 
There are many causes for refusal of  insulin therapy by 
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diabetics as well as several patient related factors for delay 
in insulin initiation. These factors have been studied by 
many researchers in Saudi Arabia in 20145 as well as oth-
er countries such as Korea6, England and United States 
(US)6-8.
In 2014, it has been estimated that the prevalence of  
insulin refusal among type 2 diabetic patients in Saudi 
Arabia was 34.6%5.  The refusal of  insulin is a problem 
worldwide, not just in Saudi Arabia. A study conducted in 
Korea showed that insulin refusal rate was 33.6% and pa-
tient-related factors for delay in insulin initiation included 
older age, shorter duration of  diabetes and lower glycated 
haemoglobin (HBA1c)6. The study conducted in London 
by Khan et al among Bangladeshi patients with poorly 
controlled type 2 diabetes showed that 20.3% refused to 
commence insulin therapy despite repeated counseling7 
and in another study conducted by Karter et al in the US 
revealed that 35% refused insulin for many reasons8.
The aim of  the current study was to measure the refusal 
rate of  insulin therapy among type 2 diabetic patients in 
2017, to assess their perception towards insulin therapy 
and enumerate the most significant barriers to refusal of  
insulin intake.  
Methods
A cross–sectional study was conducted at the primary 
health care clinics in King Khaled University Hospital, 
Riyadh, Saudi Arabia, where patients with type 2 diabetes 
mellitus attending theclinics during the months of  Feb-
ruary and March 2017 were invited to participate in the 
study. The aim and rationale of  the study were explained 
to each participant. An informed consent was signed by 
every patient included in the study. All type 1 diabetic 
patients, those below the age of  30 years and gestational 
diabetes have been excluded excluded from the study. 
Sampling:
In order to calculate the sample size we hypothesized that 
34.6% of  Saudi type 2 diabetic patients refused insulin 
therapy based on a study conducted in 20145. With a sig-
nificance level of  95% (Z = 1.96), a margin error of  5% 
(d = 0.05) and by using the formula (n = Z^2p (1-p)/d2), 
the minimal required sample size was estimated to be 348 
with 10% non-response rate.
Data collection:
Trained personnel were used to interview patients and fill 
out a pre-prepared questionnaire. The questionnaire was 
divided into three sections: socio-demographic informa-
tion, medical history and perceived barriers to use insulin. 
The section in questionnaire concerning insulin barriers 
has been adopted and modified from other studies5,6,7,8. 
A health belief  model was constructed where five points 
Likert scale was used to measure patients’ perception and 
barriers towards insulin therapy. The scale ranged from 
‘strongly agree’ to ‘strongly disagree’. The highest score 
was 5 and the lowest score was 1. Fifteen statements were 
used to compose this scale. The sum of  the factors within 
this scale ranged from 15 to 75 points. Data regarding 
HbA1c levels and any diabetic complications were re-
trieved from the patients’ medical records. 
 
Pilot study:
A pilot study was conducted for 10 participants to test the 
questionnaire feasibility and the reliability of  Likert scale 
where krobach’s alpha was 74.2%.
 
Statistical analysis:
Data were analyzed using SPSS software, version 23 (SPSS 
Inc., Chicago, Illinois, USA). The categorical variables in 
the study were presented as percentages. The chi-square 
test was used for comparison. Analysis was carried out at 
a significance level of  0.05 (p<0.05). 
The study was approved by the Institutional Review 
Board (IRB) of  the College of  Medicine and performed 
in accordance with the ethical standards.
 
Results:
The study included 402 type 2 diabetic patients, where 152 
(37.8%) were males. Their ages ranged from 30 to over 70 
years. More than one third of  the patients (37.8%) were 
in the age group 51-60 years. Nearly, one-third (32.1%) 
were uneducated. 
Only 23.9% of  population study had controlled diabe-
tes (HbA1c ≤ 7) while the majority (76.1%) were uncon-
trolled. Among the controlled group, 63 patients (65.6%) 
accepted insulin therapy while 33 patients (34.4%) re-
fused it. On the other hand, 79% of  the uncontrolled 
group accepted insulin therapy and 21% refused. The 
difference between the two groups was statistically signif-
icant (p=0.008).
Among the participants enrolled, 242 (60.2%) were using 
OHDs while the rest 160 (39.8%) were already on insu-
lin. Concerning the acceptance of  insulin use, 98 patients 
(24.4%) refused insulin injections. None of  elements of  
the socio-demographic data was statistically significantly 
different between the two groups (Table 1). 
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The perceived barriers to insulin therapy amongst all pa-
tients are shown in Table 2. The mean of  the items' sum 
was 46.4 + 8.7 which indicated poor perception towards 
insulin therapy. It is worth mentioning that most of  the 
patients (87.6%) take treatment information from their 
physicians, yet, refusal rate was still high.  After combin-
ing the two categories of  ‘strongly agree’ and ‘agree’, five 
statements represented the most prominent perceived 
barriers amongst patients on OHDs in comparison with 
those on insulin therapy. The statements were: (1) using 
insulin means reaching end-stage diabetes, (2) using in-
sulin means failure of  a diabetic to take care of  his/her 
health, (3) using insulin can cause anxiety because I don't 
know the right way to inject it, (4) injecting insulin re-
quires the help of  others and finally, (5) fear of  injections. 
In addition, two social factors have been recognized as 
significant barriers to insulin therapy, namely the restric-
tion of  daily life activities and feeling different from oth-
ers. 
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Hypertension Hyperlipidemia Cardiovascular disease Other 
Accept or refuse insulin therapy according to patients'   
comorbidity
Has it and accept Has it and refuse Doesn't have and accept Doesn't have and refuse 
Regarding the control of  diabetes, most of  the uncon-
trolled diabetic patients, 241 (79%), accepted insulin ther-
apy versus 64 (21%) uncontrolled patients who refused to 
receive insulin; the difference was statistically significant, 
(p=0.008) (Table 3).                                                                 
Hypertension was reported in 248 (61.7%) patients, hy-
perlipidemia in 256 (63.7%) patients, cardiovascular dis-
ease in 68 (16.9%) patients and 88 patients (21.9%) had 
other chronic diseases (Figure 1).  It was found that only 
hyperlipidemia showed a statistically significant differ-
ence (p= 0.006) regarding acceptance or refusal of  insu-
lin injections. 
During the conduction of  the study, special interest was 
directed towards nephropathy as the main complication 
of  diabetes.  Of  the entire study group, 118 (29.9%) pa-
tients had documented nephropathy as a complication 
while 276 (70%) did not suffer from diabetic nephropa-
thy. Within the nephropathy group, 93 (78.8%) accepted 
insulin therapy while the remaining 25 (21.2%) had re-
fused (Table 3). No statistically significant difference was 
detected between the groups with or without nephropa-
thy, (p=0.336). 
Variable Sub group Accept to use 
insulin



















Table 3: Accept or refuse taking insulin according to the control of diabetes and nephropathy as a complication.
Variable Sub group Accept to use 
insulin



























Hypertension Hyperlipidemia Cardiovascular disease Other 
Accept or refuse taking insulin according to patient chronic disease
Has it and accept Has it and refuse Doesn't have and accept Doesn't have and refuse 
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Discussion
Guidelines for management of  diabetes recommend the 
use of  OHDs as monotherapy or as combination therapy 
with or without insulin.  The oral hypoglycemic drugs are 
often initially successful in lowering the glycated hemo-
globin level but unfortunately, alone, they are unable to 
maintain normal levels of  HbA1c on the long run. Ap-
propriate timing for initiation of  insulin therapy is recom-
mended in patients who are uncontrolled, as it reduces di-
abetes-related complications, improves the cardiovascular 
profile and helps preserve β-cell function for a longer du-
ration than OHDs alone9. 
The percentage of  diabetics who refused insulin therapy 
in the current study is still high (25%), although it has 
dropped compared to a previous study done in Saudi Ara-
bia in 2014 (34.6%)5. In comparison with other countries; 
our figure is much lower than the refusal rates reported in 
Iran (77%)10, Malaysia (74.2%)11 and Singapore (70%)12. 
However, it is quite close to the figure reported in the US 
(28.2%)13.The great discrepancy between results across 
different countries could be attributed to the different in-
clusion criteria. In our study, we included type 2 diabetic 
patients only whether on OHDs or insulin therapy and 
we excluded type 1 diabetics.
None of  the socio-demographic factors were found to be 
significantly different between the groups in the current 
study, which is different from the conclusions reached in 
other studies such as in the US where females were found 
to be less likely to accept insulin therapy13. Also, in Ma-
laysia, the level of  education had a significant impact on 
the willingness to use insulin11 as well as in South Africa14. 
Participants who had controlled levels of  HbA1c were 
more reluctant to use insulin than those with uncon-
trolled levels; this finding was supported by previous 
studies conducted in Singapore12 and Korea15. Patients 
with controlled HbA1c believe that they do not require 
insulin therapy. These results are opposite to the work 
presented by Hosomura et al that discovered a higher in-
sulin therapy refusal rate among uncontrolled diabetics16. 
The study by Khan et al in London on Bangladeshi pa-
tients showed that informing patients that they require 
insulin leads to the false belief  of  being in a late stage of  
the disease with imminent, premature death. Other pa-
tients in the same study had fear of  hypoglycemia, weight 
gain and loss of  independence7. In spite of  getting infor-
mation about diabetes from their physicians, the majority 
of  participants in our study had many misconceptions, 
whether they were OHDs- or insulin-users12. Those who 
were using OHDs only tended to refuse insulin therapy 
more strongly than the insulin using group. 
Participants in our study in both groups (OHDs- and 
insulin-users) showed a negative attitude and poor per-
ception towardsinsulin therapy. Certain statements have 
been chosen as stronger barriers to insulin therapy than 
others. The most prominent reasons for refusal were fear 
of  injection, the need to be compliant with the treatment 
plans, concerns about way of  life and future and final-
ly, the perception that they reached an end-stage in the 
disease course.  Similar reasons have been mentioned 
in earlier studies and therefore, researchers stated that it 
was preferable to introduce insulin to the treatment plan 
early in the course of  the disease so that insulin would 
not be perceived as being a treatment for end-stage pa-
tients10.  Other barriers that were perceived by patients 
include weight gain, hypoglycemia and other health prob-
lems. These barriers were also reported by other studies 
as some of  the main factors that discourage patients to 
use insulin7,16. 
Another major concern that was mentioned by insulin 
naïve diabetics is the awkwardness of  being falsely rec-
ognized by the community as drug addicts due to the 
continuous use of  syringes and vials. Patients with prior 
insulin experience had fewer barriers arising from injec-
tion-related issues and worried less about the burden of  
insulin dose increments than did insulin-naive patients17. 
In the current study, concerns about the impact of  insu-
lin injections on the participants’ daily life activities were 
one of  the significant social barriers mentioned regard-
ing the intake of  insulin. Restriction of  daily life activities 
and feeling different from others were also found to be 
important by other studies11,13,15,19,20. Regarding complica-
tions of  diabetes and its impact on insulin therapy, most 
of  the patients suffering from nephropathy had accepted 
insulin. There are no reports in the literature to support 
or refute this finding or reveal any relation between di-
abetes complications and the patients’ attitude towards 
insulin.  Amongst different comorbidities, the only one 
that was statistically significant between the two groups 
was the presence of  hyperlipidemia. Dyslipidaemic pa-
tients tended to accept insulin therapy more readily than 
other group. 
Facing the stigma of  diabetes has become a must. We 
need to change the behavioral goals and eliminate certain 
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feelings associated with the disease and its treatment such 
as sense of  personal failure, low self-esteem, phobia from 
insulin injections and the negative impact of  insulin on 
social life and work. The prevalence of  diabetes mellitus 
in Saudi Arabia has been increasing during the past thirty 
years and the rate of  insulin therapy refusal is still high, 
even after decreasing from 34% in 2014 to 25% in our 
current study. Such rate is related to the negative attitude 
and poor perception of  diabetic patients towards insulin 
therapy because of  numerous social and psychological 
barriers18. Exploring patients’ worries and beliefs about 
diabetes and insulin is crucial to support physicians in de-
livering patient-centered care. Educating patients about 
the benefits of  insulin therapy and the proper way of  ad-
ministration is necessary to make patients accept insulin 
treatment more readily.  This could be achieved through 
attending support groups consisting of  insulin users to-
gether with teaching pills-only users how to deal with 
complications related to insulin use such as hypoglycemia 
and weight gain. 
 
Limitation of  the study:
The main limitation of  this study was the lower number 
of  male diabetic patients as the data collectors were fe-
males which posed some difficulty in accessing the male 
clinics. Enrolling a larger number of  patients by recruiting 
other hospitals and different health sectors will certainly 
provide a more accurate insight on all possible barriers 
perceived by patients to insulin therapy.
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